Mizuho Securities Maintains Alector(ALEC.US) With Buy Rating
Mizuho Securities Reaffirms Their Buy Rating on Alector (ALEC)
Alector (NASDAQ:ALEC Investor Three-year Losses Grow to 78% as the Stock Sheds US$52m This Past Week
BofA Securities Maintains Alector(ALEC.US) With Hold Rating, Maintains Target Price $9
Barclays Maintains Alector(ALEC.US) With Buy Rating, Maintains Target Price $12
Alector (ALEC) Receives a Buy From Barclays
Morgan Stanley Maintains Alector(ALEC.US) With Hold Rating, Maintains Target Price $10
Alector's AL002 Holds Potential Amidst Uncertainties: A Hold Rating Analysis
We Think Alector (NASDAQ:ALEC) Needs To Drive Business Growth Carefully
Alector Shares Are Trading Higher After the Company Presented Its Baseline Data for the INFRONT-Phase 3 Trial of Latozinemab at ISFTD 2024.
Express News | Alector Presents Baseline Characteristics for Pivotal Infront-3 Phase 3 Clinical Trial at the 14TH International Conference on Frontotemporal Dementias (Isftd 2024)
Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
Alector (NASDAQ:ALEC) Investors Are Sitting on a Loss of 77% If They Invested Three Years Ago
Cantor Fitzgerald Reiterates Overweight on Alector
Alector Analyst Ratings
TD Cowen Maintains Alector(ALEC.US) With Buy Rating
TD Cowen analyst Yaron Werber maintains $Alector(ALEC.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 62.4% and a total average return of 17.0% over the past year.
Alector to Participate in Upcoming Healthcare Conferences
Director & Member of Scientific Advisory Board Of Alector Sold 100% Of Their Shares
Director Richard Scheller Sells 44,250 Shares of Alector Inc (ALEC)
Mizuho Securities Maintains Alector(ALEC.US) With Buy Rating, Maintains Target Price $9
Mizuho Securities analyst Graig Suvannavejh maintains $Alector(ALEC.US)$ with a buy rating, and maintains the target price at $9.According to TipRanks data, the analyst has a success rate of 43.1%